Michael Taylor

Vice President, Toxicology

Professional Overview
Michael Taylor is a seasoned toxicology and drug safety expert with over 30 years of experience in the pharmaceutical and biotechnology industries. He currently serves as the Vice President of Toxicology at Alumis, where he oversees the company's preclinical drug safety and development programs. Additionally, he is the Founder and President of NonClinical Safety Assessment, a consultancy firm that provides expertise in toxicology and regulatory affairs.

Experience Summary

Current Role
As Vice President of Toxicology at Alumis, Michael is responsible for leading the company's preclinical development and drug safety efforts. He directs a team of toxicologists and works closely with cross-functional partners to ensure the safety and efficacy of Alumis' drug candidates. Under his leadership, the company has successfully navigated complex regulatory pathways and advanced multiple programs into clinical trials.

Career Progression
Prior to his role at Alumis, Michael held various leadership positions in the pharmaceutical industry, including Vice President of Preclinical Drug Safety at Limerick BioPharma, Vice President of Preclinical Development at Alexza Pharmaceuticals, and Executive Director of NonClinical R&D at DURECT Corporation. Throughout his career, he has demonstrated a strong track record of driving innovative drug development programs and advancing novel therapeutics.

Academic Background
Michael holds a Ph.D. in Toxicology from the University of California, Berkeley, and a Bachelor of Science degree in Biology from the University of California, Davis. He has published numerous peer-reviewed articles in leading scientific journals and is a frequent speaker at industry conferences.

Areas of Expertise

• Preclinical drug safety and toxicology

• Regulatory strategy and submission development

• Pharmacokinetics and pharmacodynamics

• Project management and cross-functional collaboration

• Leadership and team development

Professional Impact
Michael's expertise and strategic guidance have been instrumental in the successful development of several approved pharmaceutical products. He has served as an advisor to the SPARK Advisory Board at Stanford University Medical School, providing valuable insights and mentorship to early-stage biotechnology companies. Additionally, he has been recognized for his contributions to the field, including his role in establishing industry best practices for nonclinical safety assessment.

Conclusion
With his deep industry knowledge, technical expertise, and proven leadership abilities, Michael Taylor is a highly respected figure in the pharmaceutical and biotechnology sectors. He continues to drive innovation and advance drug development programs, making a significant impact on the lives of patients and the communities he serves.